Explore the words cloud of the ARREST BLINDNESS project. It provides you a very rough idea of what is the project "ARREST BLINDNESS" about.
The following table provides information about the project.
Coordinator |
LINKOPINGS UNIVERSITET
Organization address contact info |
Coordinator Country | Sweden [SE] |
Project website | http://www.arrestblindness.eu |
Total cost | 6˙030˙052 € |
EC max contribution | 5˙993˙177 € (99%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-PHC-2015-two-stage |
Funding Scheme | RIA |
Starting year | 2016 |
Duration (year-month-day) | from 2016-01-01 to 2019-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | LINKOPINGS UNIVERSITET | SE (LINKOPING) | coordinator | 1˙623˙175.00 |
2 | KLINIKUM DER UNIVERSITAET ZU KOELN | DE (KOELN) | participant | 1˙122˙407.00 |
3 | UNIVERSITAIR ZIEKENHUIS ANTWERPEN | BE (EDEGEM) | participant | 738˙065.00 |
4 | NETHERLANDS INSTITUTE FOR INNOVATIVE OCULAR SURGERY | NL (ROTTERDAM) | participant | 622˙582.00 |
5 | UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE | ES (ELCHE) | participant | 397˙656.00 |
6 | LINKOCARE LIFE SCIENCES AB | SE (LINKOPING) | participant | 321˙278.00 |
7 | OPTOMEDICAL TECHNOLOGIES GMBH | DE (LUBECK) | participant | 281˙222.00 |
8 | AEON ASTRON EUROPE B.V. | NL (LEIDEN) | participant | 277˙075.00 |
9 | AARHUS UNIVERSITET | DK (AARHUS C) | participant | 237˙165.00 |
10 | NOVALIQ GMBH | DE (HEIDELBERG) | participant | 149˙250.00 |
11 | LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG | AT (WIEN) | participant | 142˙800.00 |
12 | ACADEMISCH ZIEKENHUIS LEIDEN | NL (LEIDEN) | participant | 80˙500.00 |
13 | GENE SIGNAL INTERNATIONAL SA | CH (LAUSANNE) | participant | 0.00 |
Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medicine therapies to the clinic. The objective of ARREST BLINDNESS is therefore to develop and validate new regenerative-based therapies addressing a spectrum of blinding disorders of the cornea. These conditions either have no effective current treatments, depend on a scarce supply of donor tissue, or non-standardized methods are hindering validation of promising regenerative treatments. To achieve our objective, we will implant GMP-fabricated collagen-based bioengineered scaffolds to replace or regenerate the corneal stroma in cases of stromal thinning, scarring, dystrophy or trauma; deliver therapeutic epithelial stem and endothelial cells to the cornea to restore its transparency; deliver regenerative factors to promote neural growth and function; and actively maintain corneal immune privilege in high-risk situations by targeted therapeutic approaches to regress blood and lymphatic vessels. We will additionally develop advanced methods to image and monitor therapy throughout the cycle from GMP-compliant cell and scaffold preparation through the pre- and intra-operative stages, to postoperative follow-up and evaluation. After proof-of-concept and preclinical validation of key enabling components, these technologies will be used by one or several partners in preclinical models and in phase I/II human clinical studies. ARREST BLINDNESS directly addresses the translation of regenerative medicine, bio-artificial organs, tissue engineered scaffolds, and advanced cell and gene therapies into clinical use and will help to alleviate the worldwide problem of corneal blindness.
First study approvals package for Phase I Biocornea study | Documents, reports | 2020-01-29 12:55:43 |
Classification of LSCD by in vivo confocal microscopy | Documents, reports | 2020-01-29 12:55:43 |
Final report on minipig study results | Documents, reports | 2020-01-29 12:55:43 |
Project website and promotional materials | Websites, patent fillings, videos etc. | 2020-01-29 12:55:43 |
Dissemination and Exploitation Strategy | Websites, patent fillings, videos etc. | 2020-01-29 12:55:43 |
All approvals package for multicenter Phase II study | Documents, reports | 2020-01-29 12:55:43 |
Take a look to the deliverables list in detail: detailed list of ARREST BLINDNESS deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Federico Bech, Omar González-González, Enol Artime, Joana Serrano, Ignacio Alcalde, Juana Gallar, Jesús Merayo-Lloves, Carlos Belmonte Functional and Morphologic Alterations in Mechanical, Polymodal, and Cold Sensory Nerve Fibers of the Cornea Following Photorefractive Keratectomy published pages: 2281, ISSN: 1552-5783, DOI: 10.1167/iovs.18-24007 |
Investigative Opthalmology & Visual Science 59/6 | 2020-01-29 |
2018 |
Viet Nhat Hung Le, Ann-Charlott Schneider, Rebecca Scholz, Felix Bock, Claus Cursiefen Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-24037-3 |
Scientific Reports 8/1 | 2020-01-29 |
2018 |
Yanhong Hou, Viet Nhat Hung Le, Gábor Tóth, Sebastian Siebelmann, Jens Horstmann, Tim Gabriel, Felix Bock, Claus Cursiefen UV light crosslinking regresses mature corneal blood and lymphatic vessels and promotes subsequent high-risk corneal transplant survival published pages: 2873-2884, ISSN: 1600-6135, DOI: 10.1111/ajt.14874 |
American Journal of Transplantation 18/12 | 2020-01-29 |
2018 |
Daniele Spinozzi, Alina Miron, Marieke Bruinsma, Isabel Dapena, Itay Lavy, Perry S. Binder, Mehrdad Rafat, Silke Oellerich, Gerrit R.J. Melles Evaluation of the Suitability of Biocompatible Carriers as Artificial Transplants Using Cultured Porcine Corneal Endothelial Cells published pages: 1-7, ISSN: 0271-3683, DOI: 10.1080/02713683.2018.1536215 |
Current Eye Research | 2020-01-29 |
2018 |
Sebastian Siebelmann, Paula Scholz, Simon Sonnenschein, Björn Bachmann, Mario Matthaei, Claus Cursiefen, Ludwig M. Heindl Anterior segment optical coherence tomography for the diagnosis of corneal dystrophies according to the IC3D classification published pages: 365-380, ISSN: 0039-6257, DOI: 10.1016/j.survophthal.2017.08.001 |
Survey of Ophthalmology 63/3 | 2020-01-29 |
2018 |
Viet Nhat Hung Le, Yanhong Hou, Jens Horstmann, Felix Bock, Claus Cursiefen Novel Method to Detect Corneal Lymphatic Vessels In Vivo by Intrastromal Injection of Fluorescein published pages: 267-271, ISSN: 0277-3740, DOI: 10.1097/ico.0000000000001444 |
Cornea 37/2 | 2020-01-29 |
2017 |
Jens Horstmann, Hinnerk Schulz-Hildebrandt, Felix Bock, Sebastian Siebelmann, Eva Lankenau, Gereon Hüttmann, Philipp Steven, Claus Cursiefen Label-Free In Vivo Imaging of Corneal Lymphatic Vessels Using Microscopic Optical Coherence Tomography published pages: 5880, ISSN: 1552-5783, DOI: 10.1167/iovs.17-22286 |
Investigative Opthalmology & Visual Science 58/13 | 2020-01-29 |
2018 |
M. Notara, S. Behboudifard, M. A. Kluth, C. Maßlo, C. Ganss, M. H. Frank, B. Schumacher, C. Cursiefen UV light-blocking contact lenses protect against short-term UVB-induced limbal stem cell niche damage and inflammation published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-30021-8 |
Scientific Reports 8/1 | 2020-01-29 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ARREST BLINDNESS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ARREST BLINDNESS" are provided by the European Opendata Portal: CORDIS opendata.
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More